Drugs / autologous dendritic cell-adenovirus p53 vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00082641 | Jan 2004 → May 2009 | female breast carcinoma | University of Nebraska | Completed | No outcome recorded |
| Phase 1/2 | NCT00049218 | Apr 2003 → Jun 2007 | small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00704938 | Jun 2008 → Aug 2009 | cutaneous melanoma, renal cell carcinoma | National Institutes of Health Clinical Center (CC) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous dendritic cell-adenovirus p53 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082641 ↗ |
| Action | Deplete | “Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells.” NCT00049218 ↗ |
| Modality | Cell therapy | “autologous dendritic cell-adenovirus p53 vaccine” NCT00049218 ↗ |
| Route | Subcutaneous | “patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC)” NCT00049218 ↗ |
| Target | TP53 | “Determine the development of an anti-p53-specific immune response in these patients after treatment with this regimen.” NCT00049218 ↗ |